Please assess the completion status of the following clinical trial:

Trial Title: Efficacy, Safety, and Immunogenicity of V260 in Healthy Chinese Infants (V260-024)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy infants at least 6 weeks (42 days) and up to 12 weeks (84 days) of age at the time of the first study vaccination~* Parent/legal guardian agrees to participate by giving written informed consent and is willing and able to comply with study requirements~Exclusion Criteria:~* History of congenital abdominal disorders, prior rotavirus gastroenteritis, chronic diarrhea, failure to thrive, or abdominal surgery~* History of intussusception~* Impairment of immunological function, including Severe Combined Immunodeficiency (SCID)~* Acute disease, severe chronic disease, or chronic disease during the acute period~* Uncontrolled epilepsy, encephalopathy, seizure, or other progressive neurological disease~* Hypersensitivity to any component of the rotavirus vaccine, OPV, or DTaP~* Prior receipt of any rotavirus vaccine~* Fever, with an axillary temperature \>=37.5 °C (or equivalent) within 24 hours before study vaccination (study vaccination can be deferred until complete resolution of febrile illness)~* Clinical evidence of active gastrointestinal illness~* Received intramuscular, oral, or intravenous corticosteroid treatment since birth (topical, ophthalmic, and inhaled steroids are permitted)~* Resides in a household with an immunocompromised person~* Receipt of a blood transfusion or blood products, including immunoglobulins~* Participation in another interventional study within 14 days before the first study vaccination or during the study~* Receipt of an investigational or non-registered product other than the study vaccine within 30 days before the first study vaccination or during the study~* For participants in immunogenicity arms: inability to obtain a blood specimen at randomization visit (note: the visit may be rescheduled so that a baseline specimen may be obtained); history of polio, diphtheria, tetanus, or pertussis disease; previous vaccination against diphtheria, tetanus, pertussis, or poliomyelitis~* Any condition which, in the opinion of the investigator, may interfere with the evaluation of the study objectives

- Gender: ALL
- Minimum Age: 6 Weeks
- Maximum Age: 12 Weeks
- Healthy Volunteers: t

Study Arms:
- V260 with staggered EPI (Type: EXPERIMENTAL): V260 administered as a 2 mL oral solution at age \~2, 3, and 4 months, and staggered China Expanded Program on Immunizations (EPI) as follows: Oral poliovirus vaccine (OPV) administered as a 1 g oral solution at age \~2.5, 3.5, and 4.5 months, and diphtheria, tetanus, acellular pertussis vaccine (DTaP) administered as a 0.5 mL intramuscular injection at age \~3.5, 4.5, and 5.5 months
- Placebo with staggered EPI (Type: PLACEBO_COMPARATOR): Placebo administered as a 2 mL oral solution at age \~2, 3, and 4 months, and staggered EPI as follows: OPV administered as a 1 g oral solution at age \~2.5, 3.5, and 4.5 months, and DTaP administered as a 0.5 mL intramuscular injection at age \~3.5, 4.5, and 5.5 months
- V260 with concomitant EPI (Type: EXPERIMENTAL): V260 administered as a 2 mL oral solution at age \~2, 3, and 4 months, and concomitant EPI as follows: OPV administered as a 1 g oral solution at age \~2, 3, and 4 months and DTaP administered as a 0.5 mL intramuscular injection at age \~3, 4, and 5 months
- Placebo with concomitant EPI (Type: PLACEBO_COMPARATOR): Placebo administered as a 2 mL oral solution at age \~2, 3, and 4 months, and concomitant EPI as follows: OPV administered as a 1 g oral solution at age \~2, 3, and 4 months and DTaP administered as a 0.5 mL intramuscular injection at age \~3, 4, and 5 months

Based on this trial design, predict the completion outcome and termination type (if applicable).